Authorised psychiatrists can access products containing 3,4‑methylenedioxy‑methamphetamine (MDMA) or psilocybine for specific mental health conditions from 1 July 2023.
MDMA can be used for the treatment of post-traumatic stress disorder.
Psilocybine can be used for treatment-resistant depression.
To access products containing MDMA or psilocybine, you must be a registered psychiatrist approved under the TGA's Authorised Prescriber scheme.
-
PageMDMA can be accessed to treat post-traumatic stress disorder (PTSD). Psilocybine can be accessed for treatment-resistant depression (TRD).
-
PageClinical resources and guidance on accessing MDMA and psilocybine under the Authorised Prescriber scheme.
-
PageInformation for pharmacists on dispensing, supplying and compounding MDMA and psilocybine.
-
PageInformation for Australian sponsors on manufacturing, supplying and importing MDMA and psilocybine.
-
GuidanceGuidance on how to comply with the quality standards for MDMA (TGO 112) and psilocybine (TGO 113).